世界の抗ヒスタミン薬市場 – 2031 年までの業界動向と予測

抗ヒスタミン薬市場の分析と規模

抗ヒスタミン薬市場は、アレルギー反応におけるヒスタミンの役割についての理解が深まったことにより、近年急成長を遂げる見込みです。過敏反応の重要な媒介物であるヒスタミンは、血管拡張、筋収縮、炎症、浮腫を引き起こします。抗ヒスタミン薬は、ヒスタミンタイプ 1 (H1) 受容体をブロックすることで、アレルギーに関連する症状を効果的に緩和します。世界保健機関の「アレルギー白書 2011-2012」によると、アレルギー性鼻炎は世界人口の 10% ～ 30% に影響を及ぼし、じんましんの有病率は世界中で 20% を超えています。アレルギーの有病率が高く、若者の間で発生率も上昇しているため、予測期間中に抗ヒスタミン薬の消費が急増すると予想されます。

世界の抗ヒスタミン薬市場規模は、2023年に2億7,996万米ドルと評価され、2024年から2031年の予測期間中に9.25%のCAGRで成長し、2031年には5億6,816万米ドルに達すると予測されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Researchがまとめた市場レポートには、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

レポートの範囲と市場セグメンテーション       

市場の定義

抗ヒスタミン薬は、くしゃみ、かゆみ、涙目、鼻水など、アレルギーに関連する症状を緩和するために一般的に使用される薬の一種です。抗ヒスタミン薬は、アレルギー反応中に体内で放出される化学物質であるヒスタミンの作用を阻害することで作用します。ヒスタミンは、ヒスタミン受容体に結合することで、さまざまなアレルギー症状を引き起こします。抗ヒスタミン薬は、アレルギー症状を軽減または予防し、アレルギー、花粉症、その他のアレルギー症状に苦しむ人々を楽にします。これらの薬は、経口錠剤、点鼻薬、点眼薬、局所用クリームなど、さまざまな形で入手可能で、さまざまなアレルギー関連の症状や好みに対応しています。

抗ヒスタミン薬市場の動向

ドライバー

• アレルギー反応の増加により 抗ヒスタミン薬の需要が増加

アレルギー性鼻炎、じんましん、アレルギー性結膜炎などのアレルギー症状を経験する人が増えるにつれて、効果的な症状緩和の需要が高まっています。抗ヒスタミン薬は、かゆみ、くしゃみ、鼻づまり、皮膚の発疹などの症状を緩和することで、これらの症状の管理に重要な役割を果たします。アレルギーと利用可能な治療オプションに関する認識が広がり、抗ヒスタミン剤の処方と投与方法が進歩するにつれて、これらの医薬品の市場は、世界中のアレルギー患者の高まる医療ニーズを満たすために継続的な成長を遂げる態勢が整っています。

例えば、

In March 2023, Astepro Allergy's strategic collabortaion with Meghann Fahy underscores the commitment to addressing the global rise in allergies. This collaboration aims to enhance awareness and accessibility to Astepro, a rapid-acting nasal spray effective in alleviating allergy symptoms. The collaboration seeks to empower individuals suffering from allergies with timely relief by leveraging Fahy's platform, further contributing to the growth of the antihistamine drugs market.

• Rising Investment in the Development of Advanced Technologies Increases the Innovation in Antihistamine Drugs

Technological advancements enhance the research and development process, leading to the discovery of more effective and targeted antihistamine therapies. Improved drug delivery systems, such as nano-encapsulation and controlled-release formulations, enhance the efficacy and convenience of antihistamine medications, thereby expanding their market potential. Furthermore, advancements in diagnostic tools and genetic testing enable personalized medicine approaches, allowing for tailored antihistamine treatments based on individual patient profiles. The synergy between technological innovation and pharmaceutical development fosters growth and innovation in the antihistamine drugs market, meeting the evolving needs of patients with allergic conditions.

For Instance,

In January 2022, Antares Pharma's announcement of positive Phase I results for ATRS-1902 highlights the impact of technological advancements on the Addison's Disease Drugs Market. ATRS-1902's development represents an innovation in targeted drug delivery systems for treating acute adrenal insufficiency, aligning with the trend toward more precise and convenient management of the condition. This advancement underscores the potential for improved patient outcomes and increased demand for specialized treatments in the market.

Opportunities

• Rise of Emerging Markets due to Expanding Consumer Base Enhancing the Reach of Antihistamine Medications

As economies develop and healthcare infrastructure improves in various regions, there is a growing awareness and demand for pharmaceuticals to address allergic conditions. Antihistamine drugs, with their established efficacy in managing allergies, stand to benefit from this trend. Furthermore, factors such as urbanization, environmental changes, and increased exposure to allergens contribute to the rising prevalence of allergic disorders in emerging markets. Pharmaceutical companies can capitalize on this expanding consumer base by introducing affordable and accessible antihistamine products tailored to the specific needs of these markets, thereby driving growth and market penetration.

• Rising Development of Biological Antihistamines Increases its Demand among the Consumers

Antihistamines medications, also known as biologics, are engineered from living organisms and target specific components of the immune system involved in allergic reactions, such as histamine receptors or inflammatory mediators. Unsuch as traditional antihistamines, biological antihistamines offer targeted and potentially more effective treatment options with fewer side effects. They offer a chance for enhanced management of allergic conditions, especially in individuals who may not exhibit sufficient response to conventional antihistamines or who encounter notable side effects. The development of biological antihistamines opens avenues for personalized medicine approaches, catering to the individualized needs of patients with allergies and related conditions.

Restraints/Challenges

• Rising Side Effects of Antihistamine Drugs Reduces Patient Compliance

While these medications effectively alleviate allergy symptoms by blocking histamine receptors, they can also induce adverse reactions. Common side effects include drowsiness, dizziness, dry mouth, blurred vision, and constipation, particularly with first-generation antihistamines. Additionally, some individuals may experience paradoxical reactions, such as agitation or excitability, especially in children and the elderly. These side effects can lead to reduced patient compliance and reluctance to use antihistamine medications, thereby impacting market growth.

• Regulatory Challenges Limits the Product Availability

Stringent regulations governing drug approval processes, labeling requirements, and safety standards can significantly impact the development, manufacturing, and commercialization of antihistamine medications. Compliance with regulatory guidelines often requires substantial investments in research, clinical trials, and documentation, leading to prolonged timelines and increased costs for market entry. Moreover, variations in regulatory requirements across different regions and countries necessitate careful navigation and adaptation by pharmaceutical companies, further complicating market access and expansion efforts. These regulatory hurdles can impede innovation, limit product availability, and hinder market growth within the antihistamine drugs sector.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In December 2022, Morepen Laboratories Limited received approval from the U.S. FDA for fexofenadine hydrochloride, marketed under the brand 'Allerga.' This anti-allergy medication is used to alleviate symptoms associated with allergies and hay fever, enhancing the company's portfolio for addressing allergic conditions in the U.S. market
• In June 2021, The U.S. FDA granted approval for Astepro (azelastine hydrochloride nasal spray, 0.15 percent) to be available over the counter for individuals aged six and above. This represents a significant milestone in allergy treatment, providing nonprescription access to a nasal antihistamine for managing seasonal and perennial allergic rhinitis, commonly known as allergies
• In June 2020, Cadila Pharmaceuticals launched Bilastin syrup and tablets in India, expanding the options for allergy treatment in the country. Bilastin, an anti-allergic medication, is specifically indicated for the management of allergic rhinitis, contributing to the company's efforts in addressing the healthcare needs of individuals suffering from allergic conditions in the Indian market

Antihistamine Drugs Market Scope

The market is segmented on the basis of type, indication, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you meagre growth segments in the industries and provide the users with a valuable market overview and insights to help them make strategic decisions for identifying core market applications.

Type

• Prescription-based
• Over-the-counter (OTC)

Indication

• Urticaria
• Allergy
• Dermatitis
• Others

Dosage Form

• Tablets
• Capsules
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

 Antihistamine Drugs Market Regional Analysis/Insights

The market is analyzed, and market size insights and trends are provided by country, type, indication, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the market report is U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, rest of Middle East & Africa.

North America is expected to dominate the market due to several factors. Major key players in the pharmaceutical industry are increasingly investing in innovative technologies, driving advancements in drug development and distribution. Additionally, the region's substantial healthcare expenditure indicates a strong commitment to medical research and treatment, fostering a conducive environment for market growth. These combined factors are expected to propel North America's dominance in the antihistamine drugs market, positioning it at the forefront of global advancements in allergy and inflammation management.

The Asia-Pacific is expected to experience significant growth due to the rising incidence of allergic reactions in the population. This trend is expected to drive demand for healthcare services and products tailored to allergy management. Moreover, ongoing advancements in healthcare infrastructure across the region will play a pivotal role in facilitating access to diagnosis, treatment, and prevention services, thereby accelerating the growth trajectory of the market in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Antihistamine Drugs Market Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• Akorn Operation Company LLC (U.S.)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline(U.K.)
• Novartis AG (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Boehringer Ingelheim International GmbH. (Germany)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Bayer AG (Germany)
• Merck & Co., Inc. (U.S.)
• Prestige Consumer Healthcare Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• Almirall, S.A (Spain)
• Zenomed Healthcare Private Limited (India)
• Cadila Pharmaceuticals (India)

SKU-53442